Bauyrzhan Umbayev

Dr. Bauyrzhan Umbayev

National Laboratory Astana, Nazarbayev University
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
SASholpan Askarova
Sholpan Askarova
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
Abdul-Razak MasoudAbdul-Razak Masoud
Abdul-Razak Masoud
AKAiym Kaiyrlykyzy
Aiym Kaiyrlykyzy
Yuliya Safarova (Yantsen)Yuliya Safarova (Yantsen)
Yuliya Safarova (Yantsen)
AKAlmagul Kushugulova
Almagul Kushugulova
Gut microbiome is a community of microorganisms in the gastrointestinal tract. These bacteria have a tremendous impact on the human physiology in healthy individuals and during an illness. Intestinal microbiome can influence one's health either directly by secreting biologically active substances such as vitamins, essential amino acids, lipids et cetera or indirectly by modulating metabolic processes and the immune system. In recent years considerable information has been accumulated on the relationship between gut microbiome and brain functions. Moreover, significant quantitative and qualitative changes of gut microbiome have been reported in patients with Alzheimer's disease. On the other hand, gut microbiome is highly sensitive to negative external lifestyle aspects, such as diet, sleep deprivation, circadian rhythm disturbance, chronic noise, and sedentary behavior, which are also considered as important risk factors for the development of sporadic Alzheimer's disease. In this regard, this review is focused on analyzing the links between gut microbiome, modern lifestyle, aging, and Alzheimer's disease.

Verified
Journal Article
Open access
PDF file
DADauren Alimbetov
Dauren Alimbetov
SASholpan Askarova
Sholpan Askarova
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
TDTerence Davis
Terence Davis
DKDavid Kipling
David Kipling
Chemotherapeutic drugs target a physiological differentiating feature of cancer cells as they tend to actively proliferate more than normal cells. They have well-known side-effects resulting from the death of highly proliferative normal cells in the gut and immune system. Cancer treatment has changed dramatically over the years owing to rapid advances in oncology research. Developments in cancer therapies, namely surgery, radiotherapy, cytotoxic chemotherapy and selective treatment methods due to better understanding of tumor characteristics, have significantly increased cancer survival. However, many chemotherapeutic regimes still fail, with 90% of the drug failures in metastatic cancer treatment due to chemoresistance, as cancer cells eventually develop resistance to chemotherapeutic drugs. Chemoresistance is caused through genetic mutations in various proteins involved in cellular mechanisms such as cell cycle, apoptosis and cell adhesion, and targeting those mechanisms could improve outcomes of cancer therapy. Recent developments in cancer treatment are focused on combination therapy, whereby cells are sensitized to chemotherapeutic agents using inhibitors of target pathways inducing chemoresistance thus, hopefully, overcoming the problems of drug resistance. In this review, we discuss the role of cell cycle, apoptosis and cell adhesion in cancer chemoresistance mechanisms, possible drugs to target these pathways and, thus, novel therapeutic approaches for cancer treatment.

17 June 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
SASholpan Askarova
Sholpan Askarova
AAAigul Almabayeva
Aigul Almabayeva
TSTimur Saliev
Timur Saliev
Abdul-Razak MasoudAbdul-Razak Masoud
Abdul-Razak Masoud
DBDenis Bulanin
Denis Bulanin
Skin aging has been associated with a higher dietary intake of carbohydrates, particularly glucose and galactose. In fact, the carbohydrates are capable of damaging the skin’s vital components through nonenzymatic glycation, the covalent attachment of sugar to a protein, and subsequent production of advanced glycation end products (AGEs). This review is focused on the role of D-galactose in the development of skin aging and its relation to oxidative stress. The interest in this problem was dictated by recent findings that used in vitro and in vivo models. The review highlights the recent advances in the underlying molecular mechanisms of D-galactose-mediated cell senescence and cytotoxicity. We have also proposed the possible impact of galactosemia on skin aging and its clinical relevance. The understanding of molecular mechanisms of skin aging mediated by D-galactose can help dermatologists optimize methods for prevention and treatment of skin senescence and aging-related skin diseases.

8 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
AYAssylzhan Yessenkyzy
Assylzhan Yessenkyzy
TSTimur Saliev
Timur Saliev
MZMarina Zhanaliyeva
Marina Zhanaliyeva
Abdul-Razak MasoudAbdul-Razak Masoud
Abdul-Razak Masoud
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
TNTalgat Nurgozhin
Talgat Nurgozhin
It has been thought that caloric restriction favors longevity and healthy aging where autophagy plays a vital role. However, autophagy decreases during aging and that can lead to the development of aging-associated diseases such as cancer, diabetes, neurodegeneration, etc. It was shown that autophagy can be induced by mechanical or chemical stress. In this regard, various pharmacological compounds were proposed, including natural polyphenols. Apart from the ability to induce autophagy, polyphenols, such as resveratrol, are capable of modulating the expression of pro- and anti-apoptotic factors, neutralizing free radical species, affecting mitochondrial functions, chelating redox-active transition metal ions, and preventing protein aggregation. Moreover, polyphenols have advantages compared to chemical inducers of autophagy due to their intrinsic natural bio-compatibility and safety. In this context, polyphenols can be considered as a potential therapeutic tool for healthy aging either as a part of a diet or as separate compounds (supplements). This review discusses the epigenetic aspect and the underlying molecular mechanism of polyphenols as an anti-aging remedy. In addition, the recent advances of studies on NAD-dependent deacetylase sirtuin-1 (SIRT1) regulation of autophagy, the role of senescence-associated secretory phenotype (SASP) in cells senescence and their regulation by polyphenols have been highlighted as well. Apart from that, the review also revised the latest information on how polyphenols can help to improve mitochondrial function and modulate apoptosis (programmed cell death).

16 April 2020 in Regenerative Medicine
Verified
Journal Article
Open access
Yuliya Safarova (Yantsen)Yuliya Safarova (Yantsen)
Yuliya Safarova (Yantsen)
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
GHGonzalo Hortelano
Gonzalo Hortelano
SASholpan Askarova
Sholpan Askarova
In pathological bone conditions (e.g., osteoporotic fractures or critical size bone defects), increasing the pool of osteoblast progenitor cells is a promising therapeutic approach to facilitate bo...

27 September 2018 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
Dana AkilbekovaDana Akilbekova
Dana Akilbekova
Vyacheslav OgayVyacheslav Ogay
Vyacheslav Ogay
TYTalgat Yakupov
Talgat Yakupov
MSMadina Sarsenova
Madina Sarsenova
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
ZUZhandos N. Utegulov
Zhandos N. Utegulov
Bone fractures are widespread, especially in the elderly population and people involved in extensive physical activity (e.g., sportsmen, military personnel, and heavy load physical labor force), and their impact is pervasive. From an individual’s perspective, a fracture negatively affects the physical and mental health, whereas complicated cases such as hip fractures increase can lead to the permanent disability and increased the risk of death. Direct and indirect costs of the fracture care can be high. According to the report on Osteoporosis in the European Union, in 2010 care expenditures of the healthcare systems for the fragility fractures were €37 billion.1